Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients

Lin,Alexander; Wood,Charles; Hill-Kayser,Christine; Mick,Rosemarie; Kaiser,Larry; Metz,James

doi:10.3892/etm.2010.153

Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients

Authors:
- Alexander Lin
- Charles Wood
- Christine Hill-Kayser
- Rosemarie Mick
- Larry Kaiser
- James Metz
View Affiliations

Affiliations: Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA, Department of Surgery, The University of Texas Health Science Center at Houston, Houston, TX 77225, USA
Published online on: September 29, 2010 https://doi.org/10.3892/etm.2010.153
Pages: 1027-1033

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is significant interest in incorporating positron emission tomography (PET) into radiation therapy planning, although limited data exist that separately consider its diagnostic accuracy with respect to the primary tumor, hilum and mediastinum. This study evaluates the accuracy of PET planning by region of interest. Between January 2003 and July 2005, 351 patients with a pre-operative PET study underwent surgical resection. Of this population, 257 (73%) patients with a diagnosis of non-small cell lung cancer were evaluated. PET study findings regarding the suspected primary tumor site, ipsilateral hilum and mediastinum were correlated with surgical pathology for determination of accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). The accuracy of the primary site (95%), ipsilateral hilum (80%) and mediastinum (84%) was relatively high. The NPV of the ipsilateral hilum and mediastinum was also high (92 and 86%, respectively). However, the PPV of the ipsilateral hilum (31%) and mediastinum (75%) was lower. PET accuracy evaluating bronchoalveolar primary tumors was lower vs. other histologies (86 vs. 96%, p=0.02), although there was no difference with regard to the hilum or mediastinum. PET scanning may be an important tool in designing radiation treatment fields for lung cancer when combined with other imaging modalities. However, caution must be exercised when evaluating lymph node regions, as the PPV is not as high for the ipsilateral hilum and mediastinum as for the primary tumor. The NPV is high for nodal regions and may help with the exclusion of large treatment volumes in selected cases.

View Figures

View References

1.	Albes JM, Lietzenmayer R, Schott U, Schülen E, Wehrmann M and Ziemer G: Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg. 47:42–47. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Bury T, Paulus P, Dowlati A, Corhay JL, Weber T, Ghaye B, Schoffers J, Limet R, Albert A, Rigo P and Radermecker M: Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J. 9:2560–2564. 1996. View Article : Google Scholar : PubMed/NCBI
3.	Coleman RE: PET in lung cancer. J Nucl Med. 40:814–820. 1999.PubMed/NCBI
4.	Sachs S and Bilfinger TV: The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest. 128:698–703. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Gould MK, Maclean CC, Kuschner WG, Rydzak CE and Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 285:914–924. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK and Owens DK: Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 139:879–892. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Toloza EM, Harpole L and McCrory DC: Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 123:S137–S146. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Murayama S, Ishida T, Sugio K and Masuda K: The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med. 23:741–747. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, Blahd W and Williams AJ: Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 153:417–421. 1996. View Article : Google Scholar : PubMed/NCBI
10.	Vansteenkiste JF and Stroobants SG: The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J. 17:802–820. 2001. View Article : Google Scholar : PubMed/NCBI
11.	Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, Myers RW and Lutrin CL: Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 60:1573–1582. 1995. View Article : Google Scholar : PubMed/NCBI
12.	Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mortelmans LA and Demedts MG: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 16:2142–2149. 1998.PubMed/NCBI
13.	Patz EF Jr, Lowe VJ, Goodman PC and Herndon J: Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 108:1617–1621. 1995. View Article : Google Scholar : PubMed/NCBI
14.	Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, Fidler V, Pruim J and Groen HJ: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 343:254–261. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Scott WJ, Gobar LS, Terry JD, Dewan NA and Sunderland JJ: Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 111:642–648. 1996. View Article : Google Scholar : PubMed/NCBI
16.	Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K and Uno K: The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomorgraphy in patients with lung cancer. J Thorac Cardiovasc Surg. 127:1087–1092. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK and Weder W: Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 202:441–446. 1997. View Article : Google Scholar : PubMed/NCBI
18.	Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI and Orringer MB: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 191:371–377. 1994. View Article : Google Scholar : PubMed/NCBI
19.	Hagberg RC, Segall GM, Stark P, Burdon TA and Pompili MF: Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg. 12:92–97. 1997. View Article : Google Scholar
20.	Gupta NC, Tamim WJ, Graeber GG, Bishop HA and Hobbs GR: Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 120:521–527. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Dunagan D, Chin R Jr, McCain T, Case L, Harkness B, Oaks T and Haponik E: Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest. 119:333–339. 2001. View Article : Google Scholar : PubMed/NCBI
22.	Lavrenkov K, Partridge M, Cook G and Brada M: Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol. 77:1–4. 2005.PubMed/NCBI
23.	Greene FL; American Joint Committee on Cancer, American Cancer Society: AJCC Cancer Staging Manual. 6th edition. Springer-Verlag; New York: 2002, View Article : Google Scholar
24.	Fleiss JL: Statistical Methods for Rates and Proportions. 2nd edition. John Wiley and Sons, Inc; New York: 1981
25.	Bradley JD, Wahab S, Lockett MA, Perez CA and Purdy JA: Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radio-therapy fields. Int J Radiat Oncol Biol Phys. 56:342–347. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Rosenzweig KE, Sura S, Jackson A and Yorke E: Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol. 25:5557–5561. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, Li J, Liu X, Wang R, Li B, Kong L and Yin Y: A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol. 30:239–244. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M and Teule GJ: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multi-centre randomized trial. Lancet. 359:1388–1393. 2002.PubMed/NCBI
29.	Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, McCaughan BC and Fulham MJ: Randomized controlled clinical trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 22:2357–2362. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Fischer B, Lassen U, Mortensen J, et al: Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 361:32–39. 2009. View Article : Google Scholar : PubMed/NCBI
31.	López-Encuentra A, García-Luján R, Rivas JJ, Rodríguez-Rodríguez J, Torres-Lanza J and Varela-Simo G; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery: Comparison between clinical and pathologic staging in 2,994 cases of lung cancer. Ann Thorac Surg. 79:974–979. 2005.PubMed/NCBI
32.	Fernando HC and Goldstraw P: The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging. Cancer. 65:2503–2506. 1990. View Article : Google Scholar : PubMed/NCBI
33.	Gdeedo A, van Schil P, Corthouts B, van Mieghem F, van Meerbeeck J and van Marck E: Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. Eur J Cardiothorac Surg. 12:224–227. 1997.
34.	Bülzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Müller KM and Vogt-Moykopf I: New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer. 70:1102–1110. 1992.PubMed/NCBI
35.	Bülzebruck H, Drings P, Kayser K, Schulz V, Tuengerthal S and Vogt-Moykopf I: Classification of lung cancer: first experiences with the new TNM classification (4th edition). Eur Respir J. 4:1197–1206. 1991.PubMed/NCBI